Accès ouvert
2026
article
OpenAlex
Xenia M. Hart, Gerhard Gründer, Stefan Unterecker, Georgios Schoretsanitis et autres
Abstract: TDM involves measuring and interpreting drug concentrations in blood plasma or serum to optimize pharmacotherapy. In psychiatry and neurology, TDM is a well-established tool for personalized drug treatments. The AGNP-TDM task force initially published guidelines for best practice TDM in 2004, …
jp, de, si, ch, it, nl, us, gb, ca, at
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Xenia M Hart, Gerhard Gründer, Christoph Hiemke, Ivana Adamovic et autres
TDM involves measuring and interpreting drug concentrations in blood plasma or serum to optimize pharmacotherapy. In psychiatry and neurology, TDM is a well-established tool for personalized drug treatments. The AGNP-TDM task force initially published guidelines for best practice TDM in 2004, 2011, …
gb
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Friederike Amann, Gudrun Hefner, Peter Cremer-Schaeffer, Gerhard Gründer et autres
Abstract: Medical cannabis, nabiximols, dronabinol and nabilone are used for various medical conditions. Despite their pronounced pharmacokinetic variability and complex concentration-effect relationships, therapeutic drug monitoring recommendations are lacking. We aimed to identify therapeutic reference ranges based on blood concentration-clinical effect relationships. Studies …
de, us, jp, at
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Gerald Zernig
Among the many mental disorders possibly comorbid with the one of primary interest, sub-stance use disorders (SUDs; i.e., substance abuse/misuse and substance dependence) are of preëminent importance as the dropout rates are much higher for SUD than, say, depression. In order to …
at
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Xenia M. Hart, Friederike Amann, Pierre Baumann, Ursula Havemann‐Reinecke et autres
BACKGROUND: Therapeutic drug monitoring (TDM) is essential for controlling pharmacogenetic and pharmacokinetic variations and for optimizing pharmacotherapy. However, its value is often underestimated because of nonsystematic recommendations for target ranges in the literature. The purpose of this study was to emphasize transparency …
jp, de, ch, us, at
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Xenia M. Hart, Gerhard Gründer, Nicolas Ansermot, Andreas Conca et autres
BACKGROUND: For psychotic disorders (i.e. schizophrenia), pharmacotherapy plays a key role in controlling acute and long-term symptoms. To find the optimal individual dose and dosage strategy, specialised tools are used. Three tools have been proven useful to personalise drug treatments: therapeutic drug …
jp, de, ch, it, fr, au, gb, se, rs, kr, ca, nl, no, tr
(code pays fourni par la source)
2024
conference-paper
OpenAlex
Friederike Amann, M. Kochtyrev, Gerald Zernig, Gerhard Gründer et autres
For duloxetine, a therapeutic reference range (TRR) of 30–120 ng/ml is recommended to attain an optimal antidepressant effect [1]. However, the concentration-effect relationship, which forms the basis of the TRR, lacks systematic investigation. Therefore, the current range is considered preliminary. This review …
de, at, jp
(code pays fourni par la source)
2024
conference-paper
OpenAlex
Friederike Amann, Kristina Endres, Christoph Hiemke, Gerald Zernig et autres
Dose-related reference ranges (DRRs) are substance and dosage form specific blood concentration ranges predicted for a given dosage. Comparing measured blood concentrations with these calculated ranges enables the detection of pharmacokinetic peculiarities or compliance issues. Previously, a validated methodology to calculate DRRs …
de, at, jp
(code pays fourni par la source)
Accès ouvert
2024
review
OpenAlex
Friederike Amann, M. Kochtyrew, Gerald Zernig, Gerhard Gründer et autres
The concentration-effect relationship for the serotonin and norepinephrine reuptake inhibitor duloxetine forms the basis of its therapeutic concentration reference range. However, it lacks systematic investigation and the range reported in the present therapeutic drug monitoring guidelines can only be considered preliminary. A …
de, at, jp
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Katja Wesner, Christoph Hiemke, Niels Bergemann, Karin Egberts et autres
-receptor occupancy for oral and long-acting injectable (LAI) formulations. . The process of study selection followed a previously published protocol and PRISMA guidelines. A total of 2,824 articles were identified through database search and 1 article via reference list check. Thirty-four studies …
de, us, ch, at
(code pays fourni par la source)
2023
article
OpenAlex
Maike Scherf‐Clavel, Pierre Baumann, Xenia M. Hart, Heike Schneider et autres
PURPOSE: Therapeutic drug monitoring (TDM) is a well-established tool for guiding psychopharmacotherapy and improving patient care. Despite their established roles in the prescription of psychotropic drugs, the "behind the curtain" processes of TDM requests are invariably obscure to clinicians, and literature addressing …
de, us, ch, at
(code pays fourni par la source)
Accès ouvert
2022
review
OpenAlex
Luzie Eichentopf, Christoph Hiemke, Andreas Conca, Jan Engelmann et autres
Introduction: A titration within a certain therapeutic reference range presupposes a relationship between the blood concentration and the therapeutic effect of a drug. However, this has not been systematically investigated for escitalopram. Furthermore, the recommended reference range disagrees with mean steady state …
de, it, ch, se, us, at
(code pays fourni par la source)